All Topics
All Topics
Technology
Technology
AI
AI
Business
Business
Entertainment
Entertainment
News
News
Programming
Programming
Security
Security
Science
Science
Design
Design
Environment
Environment
Finance
Finance
Crypto
Crypto
Politics
Politics
Sports
Sports
Education
Education
Gaming
Gaming
Art
Art
Music
Music
Health
Health
Books
Books
Food
Food
Travel
Travel
Personal
Personal
Bluesky
Twitter
Baker's Take· 2 sources

High court halts thousands of Roundup cancer lawsuits against Bayer

By

Mr Bagel

· 5d ago

The Supreme Court ruled in favor of Bayer, blocking thousands of lawsuits that alleged the company failed to warn consumers that its Roundup weedkiller could cause cancer. The decision is a major victory for Bayer, which acquired Monsanto in 2018, and also for the Trump administration, though it may create political tension with the Make America Healthy Again movement, NBC News reported.

High court halts thousands of Roundup cancer lawsuits against Bayer

"the company failed to warn consumers that Roundup could cause cancer"

NBC News

The ruling significantly restricts one of the largest waves of product liability litigation in U.S. history, according to The Washington Post. The cases had claimed that Monsanto did not adequately warn users about the alleged cancer risks associated with Roundup.

"significantly restricts one of the largest waves of product liability litigation in U.S. history"

The Washington Post

The decision narrows the legal path for tens of thousands of plaintiffs who have argued that Roundup's active ingredient, glyphosate, is carcinogenic. Bayer has maintained that the weedkiller is safe, and the Supreme Court's ruling effectively blocks most of the remaining lawsuits from proceeding in state or federal court. The outcome hands Bayer a decisive win after years of legal battles, though it may also fuel broader public skepticism about corporate accountability and regulatory oversight.

The reporting

2 outlets covered this story. Each links to the original.

0

Comments

Sign in to join the conversation.

No comments yet. Be the first.